Ignite Creation Date:
2024-05-06 @ 7:01 PM
Last Modification Date:
2024-10-26 @ 2:58 PM
Study NCT ID:
NCT05861778
Status:
COMPLETED
Last Update Posted:
2023-12-11
First Post:
2023-04-05
Brief Title:
Evaluation of 89Zr-TLX250 PETCT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma
Sponsor:
Telix Pharmaceuticals Innovations Pty Limited
Organization:
Telix Pharmaceuticals Innovations Pty Limited
Study Overview
Official Title:
An Open-label Phase I Study to Evaluate the Safety Radiation Dosimetry and Pharmacokinetics of 89Zr-TLX250 PETCT in Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma
Status:
COMPLETED
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ZIRDOSE-CP
Brief Summary:
The study is designed to evaluate the safety tolerability radiation dosimetry and pharmacokinetics 89Zr-TLX250 also known as 89Zr-DFO-girentuximab Positron Emission TomographyComputed Tomography PETCT in adult Chinese patients with indeterminate renal masses or Suspected Recurrent Renal Clear Cell Carcinoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None